Zerenex Phase III Data Wow; Keryx Hits 52-Week High
Three weeks ago, Keryx Biopharmaceuticals Inc. CEO Ron Bentsur faced tough questions at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco about continuing delays in reporting long-term Phase III data on Zerenex (ferric citrate) for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis.
On Monday, those doubts were laid to rest when the company reported the compound met its primary and all key secondary endpoints in the study, sending shares (NASDAQ:KERX) to a 52-week high of $6.86.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter